José García-Solano1,2, María Eulalia García-Solano1, Daniel Torres-Moreno1, Pablo Carbonell3, Javier Trujillo-Santos4, Miguel Pérez-Guillermo1, Pablo Conesa-Zamora5,6. 1. Department of Pathology, Santa Lucía General University Hospital (HGUSL), 30202, Cartagena, Spain. 2. Facultad de Ciencias de la Salud, Catholic University of Murcia (UCAM), 30107, Murcia, Spain. 3. Biochemistry and Clinical Genetic Centre, Virgen Arrixaca University Hospital, 30120, Murcia, El Palmar, Spain. 4. Department of Internal Medicine, HGUSL, 30202, Cartagena, Spain. 5. Facultad de Ciencias de la Salud, Catholic University of Murcia (UCAM), 30107, Murcia, Spain. pablo.conesa@carm.es. 6. Department of Clinical Analysis, HGUSL, 30202, Cartagena, Spain. pablo.conesa@carm.es.
Abstract
BACKGROUND: In contrast to conventional colorectal carcinomas (CCs), which develop through a so-called chromosome instability or suppressor phenotype pathway, the sequence of events leading from precursor polyps/adenomas to serrated adenocarcinomas (SACs), which are more aggressive and exhibit a poorer survival than CCs, is as yet not clearly defined. Here, we aimed at detecting protein and DNA biomarkers for SAC in a series of primary colorectal polyps. METHODS: In total 303 colorectal polyps were included: 121 serrated polyps (33 hyperplastic polyps, 37 sessile serrated adenomas (SSA), 51 traditional serrated adenomas (TSA)), 143 conventional polyps (72 tubular polyps, 34 tubulovillous polyps, 37 villious adenomas), and 39 bi-phenotypic serrated-conventional polyps. The protein biomarkers tested were deduced from previously published SAC and CC expression profiling studies. A representative subset of 106 polyps was selected for DNA biomarker analyses, i.e., proto-oncogene mutation and microsatellite instability (MSI) status. In order to confer proper weight to each biomarker, a multivariate logistic regression model was employed. RESULTS: We found that serrated and conventional polyps differed in most of the SAC biomarkers tested. Of these biomarkers, FSCN1 showed the largest difference in expression (p = 0.0001). Despite sharing a serrated morphology, we found that SSAs and TSAs differed considerably with respect to anatomical location, expression of EPHB2 and PTCH1, presence of the V600E BRAF mutation and MSI status. Logistic regression analysis revealed that SSA was the polyp type that shared most biomarkers with SAC. CONCLUSION: Based on the shared presence of protein and molecular biomarkers, especially FSCN1 expression, SSA may serve as a precursor lesion of SAC. Biomarker assessment may help in discerning colorectal carcinogenic routes with distinct prognostic implications.
BACKGROUND: In contrast to conventional colorectal carcinomas (CCs), which develop through a so-called chromosome instability or suppressor phenotype pathway, the sequence of events leading from precursor polyps/adenomas to serrated adenocarcinomas (SACs), which are more aggressive and exhibit a poorer survival than CCs, is as yet not clearly defined. Here, we aimed at detecting protein and DNA biomarkers for SAC in a series of primary colorectal polyps. METHODS: In total 303 colorectal polyps were included: 121 serrated polyps (33 hyperplastic polyps, 37 sessile serrated adenomas (SSA), 51 traditional serrated adenomas (TSA)), 143 conventional polyps (72 tubular polyps, 34 tubulovillous polyps, 37 villious adenomas), and 39 bi-phenotypic serrated-conventional polyps. The protein biomarkers tested were deduced from previously published SAC and CC expression profiling studies. A representative subset of 106 polyps was selected for DNA biomarker analyses, i.e., proto-oncogene mutation and microsatellite instability (MSI) status. In order to confer proper weight to each biomarker, a multivariate logistic regression model was employed. RESULTS: We found that serrated and conventional polyps differed in most of the SAC biomarkers tested. Of these biomarkers, FSCN1 showed the largest difference in expression (p = 0.0001). Despite sharing a serrated morphology, we found that SSAs and TSAs differed considerably with respect to anatomical location, expression of EPHB2 and PTCH1, presence of the V600EBRAF mutation and MSI status. Logistic regression analysis revealed that SSA was the polyp type that shared most biomarkers with SAC. CONCLUSION: Based on the shared presence of protein and molecular biomarkers, especially FSCN1 expression, SSA may serve as a precursor lesion of SAC. Biomarker assessment may help in discerning colorectal carcinogenic routes with distinct prognostic implications.
Authors: Sara Hafezi-Bakhtiari; Lai Mun Wang; Richard Colling; Stefano Serra; Runjan Chetty Journal: Histopathology Date: 2014-11-13 Impact factor: 5.087
Authors: José García-Solano; Miguel Pérez-Guillermo; Pablo Conesa-Zamora; Jesús Acosta-Ortega; Javier Trujillo-Santos; Pablo Cerezuela-Fuentes; Markus J Mäkinen Journal: Hum Pathol Date: 2010-07-01 Impact factor: 3.466
Authors: José García-Solano; Pablo Conesa-Zamora; Javier Trujillo-Santos; Daniel Torres-Moreno; Markus J Mäkinen; Miguel Pérez-Guillermo Journal: Hum Pathol Date: 2011-12-29 Impact factor: 3.466
Authors: Douglas K Rex; Dennis J Ahnen; John A Baron; Kenneth P Batts; Carol A Burke; Randall W Burt; John R Goldblum; José G Guillem; Charles J Kahi; Matthew F Kalady; Michael J O'Brien; Robert D Odze; Shuji Ogino; Susan Parry; Dale C Snover; Emina Emilia Torlakovic; Paul E Wise; Joanne Young; James Church Journal: Am J Gastroenterol Date: 2012-06-19 Impact factor: 10.864
Authors: Sidney J Winawer; Ann G Zauber; Robert H Fletcher; Jonathon S Stillman; Michael J O'Brien; Bernard Levin; Robert A Smith; David A Lieberman; Randall W Burt; Theodore R Levin; John H Bond; Durado Brooks; Tim Byers; Neil Hyman; Lynne Kirk; Alan Thorson; Clifford Simmang; David Johnson; Douglas K Rex Journal: Gastroenterology Date: 2006-05 Impact factor: 22.682
Authors: Angeline S Andrew; John A Baron; Lynn F Butterly; Arief A Suriawinata; Gregory J Tsongalis; Christina M Robinson; Christopher I Amos Journal: Int J Mol Sci Date: 2017-03-02 Impact factor: 5.923
Authors: María González-González; José María Sayagués; Luis Muñoz-Bellvís; Carlos Eduardo Pedreira; Marcello L R de Campos; Jacinto García; José Antonio Alcázar; Patrick F Braz; Breno L Galves; Luis Miguel González; Oscar Bengoechea; María Del Mar Abad; Juan Jesús Cruz; Lorena Bellido; Emilio Fonseca; Paula Díez; Pablo Juanes-Velasco; Alicia Landeira-Viñuela; Quentin Lecrevisse; Enrique Montalvillo; Rafael Góngora; Oscar Blanco; José Manuel Sánchez-Santos; Joshua LaBaer; Alberto Orfao; Manuel Fuentes Journal: Cancers (Basel) Date: 2021-05-31 Impact factor: 6.639
Authors: Jessada Thutkawkorapin; Hovsep Mahdessian; Tom Barber; Simone Picelli; Susanna von Holst; Johanna Lundin; Laura Valle; Vinaykumar Kontham; Tao Liu; Daniel Nilsson; Xiang Jiao; Annika Lindblom Journal: Oncotarget Date: 2018-01-29